

**Drug Utilization Review Board Meeting
Minutes
September 17, 2014**

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members Present:

Lester Labus, MD., Chair
Kc Lovin, PA-C, Vice Chair
C.K. Babcock, PharmD
Scott Brown, RPh, (via phone)
Myra Chiang, MD
Karen Fitzpatrick, MD
Michel Lonsinger, PharmD
Ernest Miller, DO,
Mary Nemeth-Pyles, MSN, RN, CS
Pat Regan, PharmD
Chris Terpening, PharmD, PhD
John Vanin, MD

Members Absent:

Kate Forman PharmD

DHHR/BMS Staff Present:

Vicki Cunningham, RPh, Director of Pharmacy Services
Brian Thompson, MS, PharmD, DUR Coordinator
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Administrative Assistant

Contract Staff:

Steve Small, M.S., RPh, Rational Drug Therapy Program
Eric Sears, RPh, Molina Medicaid Solutions
Nina Bandali, PharmD, Magellan Healthcare
Giovanni Perri, MD, Magellan Healthcare

- I. **INTRODUCTIONS** - Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting. Dr. Labus welcomed two new members to the DUR board, Dr. Lonsinger and Dr. Fitzpatrick. Board and attendees introduced themselves.
- II. **APPROVAL OF THE May 21, 2014 MINUTES** - A motion was made, seconded and passed to accept the minutes of the May 21, 2014 DUR Board meeting.
- III. **OLD BUSINESS**
 - A. None
- IV. **NEW BUSINESS**

A. Speakers:

- 1 Nicole Kesty – AstraZeneca – Farxiga
- 2 Shannon Goldwater-Durata-Dalvance
- 3 Doris Makari – Medimmune – Synagis

B. Updates from August 27, 2014 P&T Committee Meeting:

- 1 Dr. Labus reviewed the changes from the August meeting and any related prior authorization criteria changes and a motion was made, seconded and approved to accept the suggested changes.
Attachment A

C. Prior Authorization Criteria

- 1 Afinitor – There was a motion to approve the draft criteria as presented. It was seconded and passed.
- 2 Anoro Ellipta – There was a motion to table the draft criteria for more research. Suggestions from the Board included the following:
 - a #2 - current diagnosis of COPD
 - b #3 – failed 30 day trial or inadequate response
 - c #4 – inhaled or systemic corticosteroid
 - d #4 – remove this criteria as it is/could be used after, not first, especially as mono- or dual-therapy would require an increase to a dual- or triple-therapy.
- 3 Dalvance - There was a motion to approve the criteria as presented. It was seconded and passed.
- 4 Duavee - There was a motion to approve the criteria with the changes listed. It was seconded and passed.
 - a #1 Add if member has a diagnosis for or history of breast cancer.
 - b #2, strike “other estrogen or”
 - c Question if breast cancer is a contraindication? – Yes it is.
- 5 Linzess – There was a motion to approve the criteria with the changes listed below. The motion was seconded and passed.
 - a #3 – Patient is 18 years of age or older
 - b #5 – Strike as pregnancy is no longer a contraindication
 - c Add note that contraindication is for category C pregnancy
- 6 Olysio – There was a motion to approve the criteria with the changes listed below. The motion was seconded and passed.
 - a #8 Revise criteria to reflect that the patient’s partner is not required to sign the consent form.
- 7 Otezla – There was a motion to approve the criteria as presented. The motion was seconded and passed.
- 8 Sovaldi – There was a motion to approve the criteria as presented. The motion was seconded and passed.
- 9 Synagis – There was a motion to approve the criteria as presented. The motion was seconded and passed.

- 10 Voltaren Gel – There was motion to approve the criteria with the changes below. The motion was seconded and passed with changes.
 - a Add GI bleeding in addition to GI ulcer diagnosis
- 11 Xolair – There was a motion to approve the criteria as presented. The motion seconded and passed.
Attachment #

IV. **REPORTS**

- A. **Molina Quarterly Report –Second Quarter 2014** - Eric Sears gave an overview of the Molina 2014 Second Quarter Report. The presentation included a review of the DUR Quarterly Overall Summary Report.
See Attachment #
- B. **Rational Drug Therapy Program** - Steve Small gave a slide presentation overview of the program activities for the second quarter. The presentation included May, June and July 2014 program summaries, edit overrides and prior authorizations. (August information was not updated and is reflecting July's statistics.)
See Attachment #

VI. **OTHER BUSINESS - OPEN TO THE FLOOR**

- A. Dr. Labus approved late arriving speaker (#3 on above list) to speak on Synagis.
- B. A motion was made, seconded and approved to keep the Synagis PA criteria as previously presented and approved.

VII. **NEXT MEETING AND ADJOURNMENT**

- A. A motion was made, seconded and approved to adjourn the meeting.
- B. The meeting concluded at 5:30p.m.
- C. The next meeting will be Wednesday, November 19, 2014 from 4:00 PM-6:00 PM located at the WVDHHR.

Submitted by:

Brian M. Thompson, PharmD